Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

RenovoRx, Inc. (RNXT)

Sector - Healthcare

Price chart

-33.56%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for their lead product candidate RenovoGem. Their therapy platform, RenovoRx Trans-Arterial Micro-Perfusion, or RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoTAMP combines their patented FDA-cleared delivery system, RenovoCath, with small molecule chemotherapeutic agents that can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. While they anticipate investigating other chemotherapeutic agents for intra-arterial delivery via RenovoTAMP, their clinical work to date has focused on gemcitabine, which is a generic drug. Their first product candidate, RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. FDA has determined that RenovoGem will be regulated as, and if approved they expect will be reimbursed as, a new oncology drug product. They have secured FDA Orphan Drug Designation for RenovoGem in their first two indications: pancreatic cancer and cholangiocarcinoma (bile duct cancer, or CCA).
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
7 2009

Contacts

Address: 546 El Camino Real, Suite B1 Los Altos, Ca 94022

Telephone: (650)-284-4433

Web page: http://www.renovorx.com/

IPO information

First Trade Date 8/26/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1.9
Shares Revised (MM) 1.9
Expected offer amount (MM) $22.2
Realized offer amount(MM) $17.1

Financial Data (last reporting year)

Market Cap (MM) $82.63
Revenues (MM) $0
Net Income (Loss) (MM) $-4.43

Voting

What do you think will happen with the RNXT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Roth Capital

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Roth Capital
CO-Managers
Maxim Group LLC

Sector: Healthcare

Tweets about $RNXT

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats